FDA expands Bayer’s Hyrnuo into first-line HER2-mutant lung cancer on September 10, 2026 Accelerated Approved Bayer Boehringer Ingelheim erbB-2 Receptor first-line therapy Hyrnuo Non-Small Cell Lung Carcinoma non-small-cell lung cancer sevabertinib United States Food and Drug Administration +